Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftazidime

FDA-approved product (injectable, injection), marketed as Ceftazidime, Ceftazidime In Dextrose Container, Ceptaz and 7 more.

Registered studies
50+
Lab records
324
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftazidime
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pyelonephritis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD02

Repurposing investigation

Ceftazidime is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 5 lab records
  • E. coli: measured active in 41 of 47 lab records
  • K. pneumoniae: measured active in 111 of 272 lab records
Open Ceftazidime in ChEMBL Registered studies below
Show the latest 150 of 324 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftazidime with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Antibiotics for Pseudomonas in Early CF

    NCT00823238 · start 2004-07

    Registered record
    Registry ID
    NCT00823238
    Conditions
    Cystic Fibrosis
    Interventions
    ceftazidime and tobramycin; inhaled tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-07
    Completion
    2008-05
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventionceftazidime and tobramycin; inhaled tobramycin
    PhasePhase 1
    Registry statusCompleted

  • Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

    NCT00153634 · start 2004-03

    Registered record
    Registry ID
    NCT00153634
    Conditions
    Cystic Fibrosis; Chronic Bronchitis
    Interventions
    IV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin; IV meropenem; IV piperacillin-tazobactam; IV ticarcillin-clavulanate; IV tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-11
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Chronic Bronchitis
    InterventionIV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

    NCT00035425 · start 2001-11

    Registered record
    Registry ID
    NCT00035425
    Conditions
    Febrile Neutropenia
    Interventions
    linezolid; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2002-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    Interventionlinezolid; vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Adverse Drug Reactions of Different Brands of Ceftazidime Injection

    NCT00173901 · start 2001-03

    Registered record
    Registry ID
    NCT00173901
    Conditions
    Infection
    Interventions
    ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2001-03
    Completion
    2002-04
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionceftazidime
    PhasePhase 4
    Registry statusUnknown

  • Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration

    NCT00752882

    Registered record
    Registry ID
    NCT00752882
    Conditions
    Pseudomonas Aeruginosa Meningitis
    Interventions
    ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    2009-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudomonas Aeruginosa Meningitis
    Interventionceftazidime
    PhasePhase 2
    Registry statusUnknown